Tesamorelin Protocol

Evidence Level: Established Evidence

Backed by a substantial human clinical trial base, often with regulatory authorization for a specific indication.

Human evidence: Randomized controlled trials supporting FDA approval for a specific indication (reduction of visceral fat in HIV-associated lipodystrophy).

Animal evidence: Preclinical GHRH-receptor pharmacology preceding human trials.

Introduction & Mechanism of Action

GHRH analog studied for GH-axis research; one formulation is FDA-approved for HIV-associated lipodystrophy.

Stabilized GHRH(1-44) analog that stimulates endogenous GH release; the only compound in this category with a specific FDA-approved indication, giving it the most robust human safety database of the GH-secretagogue group.

Receptors/targets: GHRH receptor

Areas of Research Interest

• GH-axis research
• Body-composition studies

Benefits Reported in Research

• GH-axis research
• Body-composition studies

Reported Research Dosing Range

The figures below are cited from published research literature and protocol references — they describe what has been studied, not a personal prescription or instruction.

Reported range: 1–2 mg

Reported frequency: 1× daily, subcutaneous

Reported cycle duration: 12–24 weeks

Escalation & maintenance: A dedicated weekly escalation and maintenance schedule specific to this peptide has not yet been published here — follow the dose range and frequency above, titrating conservatively from the low end, and consult a physician before adjusting.

Research Reference Data

Published research on Tesamorelin reports administration at 1–2 mg via subcutaneous route. The table below cites that published research — it is not an individualized instruction.

Reconstitution Reference

Published research protocols reconstitute a 5 mg vial with 2 mL bacteriostatic water, yielding a concentration of 2.50 mg/mL. This is cited reference information, not a personalized preparation instruction — use the general research calculator below for your own reference computation.

Research Protocol Timeline

A reference summary of how this compound is described across published research — formulation, reported administration, and reported cycle length.

Dilution Guide

Reconstitute with 2 mL bacteriostatic water

Bacteriostatic Water (BAC Water) is the only recommended diluent. Do not dilute with sterile water, normal saline, lidocaine, or any other solution unless explicitly specified by the manufacturer.

Handling Guide

General laboratory handling practice cited for reference — not a personalized instruction. Any human use should follow the guidance of a licensed physician.

Wash hands and clean the injection site with an alcohol swab. Pinch a fold of skin and insert the needle at a 45–90° angle for standard subcutaneous injection (abdomen, thigh, or upper arm). Inject slowly, withdraw, and apply gentle pressure. Rotate injection sites to reduce irritation, and dispose of needles in an approved sharps container.

Storage

Store lyophilized (powder) vials in a freezer at -20°C, protected from light. Once reconstituted with bacteriostatic water, refrigerate at 2–8°C and use within the timeframe recommended in your supplier documentation — typically 2–4 weeks.

Monitoring

Monitor for injection-site reactions and the side effects listed above. Stop use and consult a physician if severe or persistent reactions occur. This is a general monitoring guideline, not a personalized medical monitoring plan.

Side Effects

• Injection-site erythema/pruritus
• Peripheral edema
• Arthralgia
• Myalgia

Contraindications

• Active malignancy
• Pregnancy
• Pituitary tumor or history of pituitary surgery/radiation

Drug interactions

• May affect insulin sensitivity — relevant for patients on glucose-lowering medication

Safety

• Injection-site reactions
• Peripheral edema
• Arthralgia
• Theoretical glucose-tolerance effects with chronic GH-axis stimulation

Approval is indication-specific; broader anti-aging or bodybuilding use is off-label and less studied.

Expected Results & Comparison

Tesamorelin has the strongest human clinical evidence of any GHRH analog in this catalog because of its approved indication — but that approval is specific to HIV-associated visceral fat reduction, not general body-composition or anti-aging use, which remains off-label and less studied.

References

Continue